Skip to main content
. 2025 Jan 3;74(2):39. doi: 10.1007/s00262-024-03890-4

Fig. 3.

Fig. 3

Kaplan–Meier curves of progression-free survival (PFS) (a) and overall survival (OS) (b) in patients with non-small cell lung cancer treated with nivolumab and ipilimumab (NI) or nivolumab, ipilimumab, and chemotherapy (NICT) after propensity score matching. Abbreviations: HR hazard ratio, CI confidence interval, mo months